TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03468491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined training
Description: The whole intervention period will last for 6 weeks, 2 visits per week, 1 hour per visit in the Research Building Room 630 of National Yang Ming University. All programs will be under the supervision of a physiotherapist with 2-year experience individually. 1. Hallux valgus correction: 1.1 Joint alignment correction (Grade II joint mobilization, 10 times/set, 3 sets/visit) - 1st MTP joint distraction - Proximal talofibular joint anteroposterior glide - (Grade III joint mobilization if any restriction being found) 1.2 Biomechanical taping (using Dynamic taping, 1 time/ visit, keep the taping for 2 days minimum) 1.3 Foot intrinsic muscle strengthening (10 times/set for each exercise, 3 sets/visit): - Short foot exercise - Toespread out exercise - Heel-rise exercises 2. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 2.1 Single lunge 2.2 Stepping down 2.3 Vertical squat 2.4 Vertical jumping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proximal training
Description: 1. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 1.1 Single lunge 1.2 Stepping down 1.3 Vertical squat 1.4 Vertical jumping All exercises will first start on firm surface without additional resistance/weight. Later, settings will be gradually shifted into on firm surface with resisted band from random direction, on a cushion with/ without resisted band, on a BOSU balance trainer. Progression are made every 2 weeks ideally, while adjustments may be taken into concern due to individual differences.
Study: NCT02236260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture will be performed using an electrical stimulator (generating electrical stimulation) for electroacupuncture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (lidocaine hydrochloride)
Description: All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthesia (lidocaine hydrochloride)
Description: All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.
Study: NCT01270438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT01441648

Intervention type: OTHER
Intervention: contact lens wear
Description: tinted contact lens wear
Study: NCT04311866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic pants
Description: The use of synthetic materials is preferred (glass fiber), resistance, durability and low weight makes them optimal. To give some extra strenght to the cast, fiber strips are placed anterior and posterior at the level of the groin, this can facilitate the transportation of the patient avoiding the use of a bar.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spica cast
Description: The use of the spica cast is a standard practice for the management of the femoral shaft fractures, however its use, under some circumstances has been related to a wrong management of the cast, auto-retrieval, patient discomfort, and a difficult situation trying to maintain personal hygiene for the patient.
Study: NCT02583451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet matching lemborexant
Description: Tablet form taken orally at bedtime.
Study: NCT03856424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 1
Description: Pressure support ventilation (PSV) modality

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 1
Description: Pressure support ventilation (PSV) modality
Study: NCT00488839

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 35 mg
Description: IPX056 Extended Release capsule containing 35 mg baclofen
Study: NCT03856424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 1
Description: Pressure support ventilation (PSV) modality

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 2
Description: T-Piece modality
Study: NCT02583451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet matching lemborexant
Description: Tablet form taken orally at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet matching zopiclone
Description: Tablet form taken orally at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet matching zopiclone
Description: Tablet form taken orally at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet matching zopiclone
Description: Tablet form taken orally at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet matching zopiclone
Description: Tablet form taken orally at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Description: 7.5 mg tablet taken orally at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 2.5 mg
Description: 2.5 tablet taken orally at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Description: 5 mg tablet taken orally at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: 10 mg tablet taken orally at bedtime.
Study: NCT00890383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetrastarch (Voluven)
Description: Goals directed volume therapy for severe trauma resuscitation
Study: NCT03936205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients allocated to this group receive a combination of Morphine and Dexmedetomidine
Study: NCT01786993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing
Description: Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Biventricular Pacing
Description: Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
Study: NCT03896022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure with Beads
Description: Single-use gold-plated 1.2mm beads/balls attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture with Needles
Description: Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
Study: NCT00488839

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056 20 mg
Description: Placebo capsule for IPX056 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056 20 mg
Description: Placebo capsule for IPX056 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056 20 mg
Description: Placebo capsule for IPX056 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056 40 mg
Description: Placebo capsule for IPX056 40 mg
Study: NCT03856424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 2
Description: T-Piece modality

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 2
Description: T-Piece modality

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 2
Description: T-Piece modality
Study: NCT03896022

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Adhesive Disks
Description: Single-use adhesive disks without needles or beads.
Study: NCT00488839

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056 40 mg
Description: Placebo capsule for IPX056 40 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056 40 mg
Description: Placebo capsule for IPX056 40 mg
Study: NCT00774202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan, Cyclophosphamide, Vincristine, Prednisone
Description: 'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Higher Dose of Rituximab
Description: rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
Study: NCT04070599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of biological samples
Description: A collection of biological samples will be carried out, with the remainders of the immunological samples taken on dry tube: the serum of the patients, taken at the initial diagnosis, will be kept frozen at -20 ° C.
Study: NCT04135456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).
Study: NCT03856424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 2
Description: T-Piece modality

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 2
Description: T-Piece modality
Study: NCT01954576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Study: NCT04182178

Intervention type: OTHER
Intervention: 10 years follow up
Description: Questionnaires
Study: NCT03504319

Intervention type: OTHER
Intervention: Exposure to high-fat smoothie
Description: Both groups will drink the high-fat smoothie and the study team will observe how they respond metabolically in the subsequent four hours using metabolic analyzer and blood draws.
Study: NCT04135456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).
Study: NCT02437539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 68Ga-NOTA-AE105
Description: One injection of 68Ga-NOTA-AE 105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography scans
Description: Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
Study: NCT01223313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Woman's Condom
Description: The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
Study: NCT02882802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Recovery Education Class
Description: Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
Study: NCT04139811

Intervention type: OTHER
Group type: OTHER
Intervention: Pars Plana Vitrectomy
Description: vitrectomy with and without ILM peeling

Intervention type: OTHER
Group type: OTHER
Intervention: Pars Plana Vitrectomy
Description: vitrectomy with and without ILM peeling
Study: NCT01070004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real driving situation
Description: Continuous blue light exposure during driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving simulator
Description: 15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
Study: NCT00647231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKT-500 Topical Patch
Description: Treatment with Ketoprofen Topical Patch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Treatment with placebo patch
Study: NCT03856424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 3
Description: High-flow oxygen

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 3
Description: High-flow oxygen

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 3
Description: High-flow oxygen
Study: NCT03471689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Participants will be trained to use mindfulness meditation to reduce pain perception.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive reappraisal
Description: Participants will be trained to use positive reappraisal to reduce pain perception.
Study: NCT02235766

Intervention type: OTHER
Intervention: Echocardiographic assessment
Study: NCT04083989

Intervention type: OTHER
Intervention: Integrative medicine-based multimodal treatment
Description: Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
Study: NCT01863017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Study: NCT03856424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 3
Description: High-flow oxygen

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 3
Description: High-flow oxygen
Study: NCT04529577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His-bundle pacing
Description: A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His-bundle pacing
Description: A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup.
Study: NCT03054844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine will be administered before administration of midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine and midazolam (PREMIX)
Description: Lidocaine will be administered as a mixture with midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
Study: NCT01977118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: streptokinase
Description: 50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline irrigation
Description: 100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
Study: NCT03893448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq™
Description: A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentacel™
Description: A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™
Description: A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
Study: NCT05287802

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance and proprioception exercises
Description: Balance and proprioception exercises using two different methods (classical balance training and Biodex) in addition to strengthening exercises
Study: NCT03893448

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RECOMBIVAX HB™
Description: A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.